Edition:
United States

Theratechnologies Inc (TH.TO)

TH.TO on Toronto Stock Exchange

2.90CAD
4:00pm EST
Change (% chg)

$-0.01 (-0.34%)
Prev Close
$2.91
Open
$2.92
Day's High
$2.97
Day's Low
$2.88
Volume
118,365
Avg. Vol
120,045
52-wk High
$3.74
52-wk Low
$1.26

TH.TO

Chart for TH.TO

About

Theratechnologies Inc. is a Canada-based specialty pharmaceutical company. The Company addresses medical needs in metabolic disorders to promote healthy ageing among human immunodeficiency virus (HIV) patients. The Company's product, EGRIFTA (tesamorelin for injection), is used for the reduction of excess abdominal fat in... (more)

Overall

Beta: 1.94
Market Cap(Mil.): $207.53
Shares Outstanding(Mil.): 71.32
Dividend: --
Yield (%): --

Financials

  TH.TO Industry Sector
P/E (TTM): 266.97 30.04 30.65
EPS (TTM): 0.01 -- --
ROI: 2.13 15.86 15.23
ROE: 3.22 16.96 16.56

BRIEF-Theratechnologies announces filing of final short form prospectus

* Theratechnologies announces the filing of a final short form prospectus Source text for Eikon: Further company coverage:

Nov 25 2016

BRIEF-Theratechnologies announces $16.5 mln bought deal financing

* Theratechnologies announces $16.5 million bought deal financing

Nov 14 2016

BRIEF-Theratechnologies announces end of patient treatment for late-stage ibalizumab trial

* Announces end of patient treatment for phase III ibalizumab trial Source text for Eikon: Further company coverage:

Oct 24 2016

BRIEF-Theratechnologies Inc Q3 EPS C$0.01

* Theratechnologies announces financial results for third quarter of 2016

Oct 04 2016

BRIEF-Theratechnologies announces financial results for third quarter of 2016

* Theratechnologies announces financial results for third quarter of 2016

Oct 04 2016

CANADA STOCKS-Futures flat as investors await OPEC pact details

Sept 29 Stock futures for Canada's main stock exchange were little changed on Thursday as investors awaited more clarity on a surprise output cut agreement by OPEC to rebalance a glut.

Sep 29 2016

BRIEF-Theratechnologies to move forward with development of new single vial formulation for EGRIFTA

* Theratechnologies to move forward with development of new single vial formulation for EGRIFTA(R)(Tesamorelin for injection) Source text for Eikon: Further company coverage:

Sep 28 2016

BRIEF-Theratechnologies posts Q2 loss per share C$0.01

* Theratechnologies announces financial results for second quarter of 2016

Jul 05 2016

Earnings vs. Estimates